Founded in 2005 by Dr. Chris Centeno and Dr. John Schultz, Regenexx pioneered the field of Interventional Orthopedics, a non-surgical approach to treating musculoskeletal (i.e. MSK or orthopedic) conditions using the body's own biology, specifically bone marrow concentrate and platelet-rich plasma, to facilitate natural healing.
The Regenexx Corporate Program packages this clinical innovation as a no PEPM, utilization based, employee benefit for self-funded employers through their existing claims process. This program reduces MSK spend by up to 70% and total medical spend by up to 10%. With 3,500+ active employer clients, 2.5 million covered lives, the program has a proven track record backed by a 95%+ client retention rate since 2015.
The clinical network spans across the U.S with 200+ board-certified physicians, supported by proprietary technology and image-guided injection protocols. Regenexx has published 46+ peer-reviewed studies and roughly half of all worldwide research on bone marrow concentrate for orthopedic injuries. Third parties such as DUKE University, have published data showing significant cost savings and positive outcomes versus the cost and failure of many common orthopedic surgeries.
The program integrates seamlessly with existing health plans through partnerships with 125+ TPAs/Carriers and ~100 stop-loss carriers, with onboarding in as little as two weeks at zero cost to the plan.
Claimed
